The Role of Calcitonin Gene Related Peptide (CGRP) in Neurogenic Vasodilation and Its Cardioprotective Effects

Zizheng Kee, Xenia Kodji, Susan D Brain, Zizheng Kee, Xenia Kodji, Susan D Brain

Abstract

Calcitonin gene-related peptide (CGRP) is a highly potent vasoactive peptide released from sensory nerves, which is now proposed to have protective effects in several cardiovascular diseases. The major α-form is produced from alternate splicing and processing of the calcitonin gene. The CGRP receptor is a complex composed of calcitonin like receptor (CLR) and a single transmembrane protein, RAMP1. CGRP is a potent vasodilator and proposed to have protective effects in several cardiovascular diseases. CGRP has a proven role in migraine and selective antagonists and antibodies are now reaching the clinic for treatment of migraine. These clinical trials with antagonists and antibodies indicate that CGRP does not play an obvious role in the physiological control of human blood pressure. This review discusses the vasodilator and hypotensive effects of CGRP and the role of CGRP in mediating cardioprotective effects in various cardiovascular models and disorders. In models of hypertension, CGRP protects against the onset and progression of hypertensive states by potentially counteracting against the pro-hypertensive systems such as the renin-angiotensin-aldosterone system (RAAS) and the sympathetic system. With regards to its cardioprotective effects in conditions such as heart failure and ischaemia, CGRP-containing nerves innervate throughout cardiac tissue and the vasculature, where evidence shows this peptide alleviates various aspects of their pathophysiology, including cardiac hypertrophy, reperfusion injury, cardiac inflammation, and apoptosis. Hence, CGRP has been suggested as a cardioprotective, endogenous mediator released under stress to help preserve cardiovascular function. With the recent developments of various CGRP-targeted pharmacotherapies, in the form of CGRP antibodies/antagonists as well as a CGRP analog, this review provides a summary and a discussion of the most recent basic science and clinical findings, initiating a discussion on the future of CGRP as a novel target in various cardiovascular diseases.

Keywords: CGRP; heart failure; humans; hypertension; neurogenic vasodilation; rodents.

Figures

FIGURE 1
FIGURE 1
Splicing and post-translational processing of the complete CGRP peptide from the CALCA gene, vesicular packaging, and release from sensory nerves. Exons 1,2,3,5, and 6 of the CALCA gene are transcribed to form the CGRP mRNA which is then translated to protein. Post-translational cleavage produces the complete 37-amino acid CGRP peptide. CGRP is packaged and co-released with substance P in a calcium dependent manner due to depolarization or via activation of TRPA1 or TRPV1 channels.
FIGURE 2
FIGURE 2
Receptors for CGRP, formed by association of either CTR or CLR with RAMP1. Sizes of different agonists indicate relative potencies at each receptor complex. CGRP and amylin are equally potent at the CTR/RAMP1 receptor complex while CGRP is more potent at the CLR/RAMP1 complex, the classical CGRP receptor.

References

    1. Alevizaki M., Shiraishi A., Rassool F. V., Ferrier G. J., MacIntyre I., Legon S. (1986). The calcitonin-like sequence of the beta CGRP gene. FEBS Lett. 206 47–52. 10.1016/0014-5793(86)81338-2
    1. Al-Rubaiee M., Gangula P. R., Millis R. M., Walker R. K., Umoh N. A., Cousins V. M., et al. (2013). Inotropic and lusitropic effects of calcitonin gene-related peptide in the heart. Am. J. Physiol. Heart Circ. Physiol. 304 H1525–H1537. 10.1152/ajpheart.00874.2012
    1. Amara S. G., Jonas V., Rosenfeld M. G., Ong E. S., Evans R. M. (1982). Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298 240–244. 10.1038/298240a0
    1. Anand I. S., Gurden J., Wander G. S., O’Gara P., Harding S. E., Ferrari R., et al. (1991). Cardiovascular and hormonal effects of calcitonin gene-related peptide in congestive heart failure. J. Am. Coll. Cardiol. 17 208–217. 10.1016/0735-1097(91)90729-S
    1. Ashina M., Bendtsen L., Jensen R., Schifter S., Olesen J. (2000). Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain 86 133–138. 10.1016/S0304-3959(00)00232-3
    1. Aubdool A. A., Kodji X., Abdul-Kader N., Heads R., Fernandes E. S., Bevan S., et al. (2016). TRPA1 activation leads to neurogenic vasodilatation: involvement of reactive oxygen nitrogen species in addition to CGRP and NO. Br. J. Pharmacol. 173 2419–2433. 10.1111/bph.13519
    1. Aubdool A. A., Thakore P., Argunhan F., Smillie S.-J., Schnelle M., Srivastava S., et al. (2017). A novel α-calcitonin gene-related peptide analogue protects against end-organ damage in experimental hypertension, cardiac hypertrophy, and heart failure. Circulation 136 367–383. 10.1161/CIRCULATIONAHA.117.028388
    1. Bandell M., Story G. M., Hwang S. W., Viswanath V., Eid S. R., Petrus M. J., et al. (2004). Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 41 849–857. 10.1016/S0896-6273(04)00150-3
    1. Bánvölgyi Á, Pálinkás L., Berki T., Clark N., Grant A. D., Helyes Z., et al. (2005). Evidence for a novel protective role of the vanilloid TRPV1 receptor in a cutaneous contact allergic dermatitis model. J. Neuroimmunol. 169 86–96. 10.1016/j.jneuroim.2005.08.012
    1. Bell D., McDermott B. J. (1996). Calcitonin gene-related peptide in the cardiovascular system: characterization of receptor populations and their (patho)physiological significance. Pharmacol. Rev. 48 253–288.
    1. Bergdahl A., Valdemarsson S., Nilsson T., Sun X. Y., Hedner T., Edvinsson L. (1999). Dilatory responses to acetylcholine, calcitonin gene-related peptide and substance P in the congestive heart failure rat. Acta Physiol. Scand. 165 15–23. 10.1046/j.1365-201x.1999.00456.x
    1. Bigal M. E., Dodick D. W., Rapoport A. M., Silberstein S. D., Ma Y., Yang R., et al. (2015). Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 14 1081–1090. 10.1016/S1474-4422(15)00249-5
    1. Bigal M. E., Walter S., Bronson M., Alibhoy A., Escandon R. (2014). Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia 34 968–976. 10.1177/0333102414527646
    1. Bodkin J. V., Thakore P., Aubdool A. A., Liang L., Fernandes E. S., Nandi M., et al. (2014). Investigating the potential role of TRPA1 in locomotion and cardiovascular control during hypertension. Pharmacol. Res. Perspect. 2:e00052 10.1002/prp2.52
    1. Booe J. M., Warner M. L., Roehrkasse A. M., Hay D. L., Pioszak A. A. (2018). Probing the mechanism of receptor activity–modifying protein modulation of GPCR ligand selectivity through rational design of potent adrenomedullin and calcitonin gene-related peptide antagonists. Mol. Pharmacol. 93 355–367. 10.1124/mol.117.110916
    1. Bracci-Laudiero L., Aloe L., Buanne P., Finn A., Stenfors C., Vigneti E., et al. (2002). NGF modulates CGRP synthesis in human B-lymphocytes: a possible anti-inflammatory action of NGF? J. Neuroimmunol. 123 58–65. 10.1016/S0165-5728(01)00475-1
    1. Brain S. D., Grant A. D. (2004). Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol. Rev. 84 903–934. 10.1152/physrev.00037.2003
    1. Brain S. D., Williams T. J., Tippins J. R., Morris H. R., MacIntyre I. (1985). Calcitonin gene-related peptide is a potent vasodilator. Nature 313 54–56. 10.1038/313054a0
    1. Bühlmann N., Leuthäuser K., Muff R., Fischer J. A., Born W. (1999). A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1. Endocrinology 140 2883–2890. 10.1210/endo.140.6.6783
    1. Cardinal R., Nadeau R., Laurent C., Boudreau G., Armour J. A. (1996). Reduced capacity of cardiac efferent sympathetic neurons to release noradrenaline and modify cardiac function in tachycardia-induced canine heart failure. Can. J. Physiol. Pharmacol. 74 1070–1078. 10.1139/y96-112
    1. Caterina M. J., Schumacher M. A., Tominaga M., Rosen T. A., Levine J. D., Julius D. (1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 816–824. 10.1038/39807
    1. Cernuda-Morollón E., Ramón C., Martínez-Camblor P., Serrano-Pertierra E., Larrosa D., Pascual J. (2015). Onabotulinumtoxin a decreases interictal CGRP plasma levels in patients with chronic migraine. Pain 156 820–824. 10.1097/j.pain.0000000000000119
    1. Chakravarty P., Suthar T. P., Coppock H. A., Nicholl C. G., Bloom S. R., Legon S., et al. (2000). CGRP and adrenomedullin binding correlates with transcript levels for calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) in rat tissues. Br. J. Pharmacol. 130 189–195. 10.1038/sj.bjp.0702975
    1. Csillik B., Tajti L., Kovács T., Kukla E., Rakic P., Knyihár-Csillik E. (1993). Distribution of calcitonin gene-related peptide in vertebrate neuromuscular junctions: relationship to the acetylcholine receptor. J. Histochem. Cytochem. 41 1547–1555. 10.1177/41.10.8245413
    1. Deng P.-Y., Li Y.-J. (2005). Calcitonin gene-related peptide and hypertension. Peptides 26 1676–1685. 10.1016/j.peptides.2005.02.002
    1. Deng P.-Y., Ye F., Cai W.-J., Deng H.-W., Li Y.-J. (2004). Role of calcitonin gene-related peptide in the phenol-induced neurogenic hypertension in rats. Regul. Pept. 119 155–161. 10.1016/j.regpep.2004.01.011
    1. Deng P.-Y., Ye F., Zhu H.-Q., Cai W.-J., Deng H.-W., Li Y.-J. (2003). An increase in the synthesis and release of calcitonin gene-related peptide in two-kidney, one-clip hypertensive rats. Regul. Pept. 114 175–182. 10.1016/S0167-0115(03)00124-1
    1. Depre C., Antalik L., Starling A., Koren M., Eisele O., Lenz R. A., et al. (2018). A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. headache. Headache 58 715–723. 10.1111/head.13316
    1. Dickerson I. M. (2013). Role of CGRP-Receptor Component Protein (RCP) in CLR/RAMP function. Curr. Protein Pept. Sci. 14 407–415. 10.2174/13892037113149990057
    1. Dodick D. W., Ashina M., Brandes J. L., Kudrow D., Lanteri-Minet M., Osipova V., et al. (2018a). ARISE: a Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38 1026–1037. 10.1177/0333102418759786
    1. Dodick D. W., Silberstein S. D., Bigal M. E., Yeung P. P., Goadsby P. J., Blankenbiller T., et al. (2018b). Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319 1999–2008. 10.1001/jama.2018.4853
    1. Dodick D. W., Goadsby P. J., Silberstein S. D., Lipton R. B., Olesen J., Ashina M., et al. (2014). Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 13 1100–1107. 10.1016/S1474-4422(14)70209-1
    1. Doi Y., Kudo H., Nishino T., Kayashima K., Kiyonaga H., Nagata T., et al. (2001). Synthesis of calcitonin gene-related peptide (CGRP) by rat arterial endothelial cells. Histol. Histopathol. 16 1073–1079. 10.14670/HH-16.1073
    1. Dong Y.-L., Vegiraju S., Gangula P. R., Kondapaka S. B., Wimalawansa S. J., Yallampalli C. (2002). Expression and regulation of calcitonin gene-related Peptide receptor in rat placentas. Biol. Reprod. 67 1321–1326. 10.1093/biolreprod/67.4.1321
    1. Doods H., Hallermayer G., Wu D., Entzeroth M., Rudolf K., Engel W., et al. (2000). Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol. 129 420–423. 10.1038/sj.bjp.0703110
    1. Eberhardt M., Stueber T., de la Roche J., Herzog C., Leffler A., Reeh P. W., et al. (2017). TRPA1 and TRPV1 are required for lidocaine-evoked calcium influx and neuropeptide release but not cytotoxicity in mouse sensory neurons. PLoS One 12:e0188008 10.1371/journal.pone.0188008
    1. Edvinsson L. (2005). Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks. CNS Drug Rev. 11 69–76. 10.1111/j.1527-3458.2005.tb00036.x
    1. Edvinsson L., Ekman R., Thulin T. (1989). Reduced levels of calcitonin gene-related peptide (CGRP) but not substance P during and after treatment of severe hypertension in man. J. Hum. Hypertens. 3 267–270.
    1. Edvinsson L., Goadsby P. (1995). Neuropeptides in the cerebral circulation: relevance to headache. Cephalalgia 15 272–276. 10.1046/j.1468-2982.1995.1504272.x
    1. Edvinsson L., Villalón C. M., MaassenVanDenBrink A. (2012). Basic mechanisms of migraine and its acute treatment. Pharmacol. Ther. 136 319–333. 10.1007/s13311-017-0592-1
    1. Edwards R. M., Trizna W. (1990). Calcitonin gene-related peptide: effects on renal arteriolar tone and tubular cAMP levels. Am. J. Physiol. 258 F121–F125. 10.1152/ajprenal.1990.258.1.F121
    1. Escott K. J., Brain S. D. (1993). Effect of a calcitonin gene-related peptide antagonist (CGRP8-37) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve. Br. J. Pharmacol. 110 772–776. 10.1111/j.1476-5381.1993.tb13878.x
    1. Evans B. N., Rosenblatt M. I, Mnayer L. O., Oliver K. R., Dickerson I. M. (2000). CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J. Biol. Chem. 275 31438–31443. 10.1074/jbc.M005604200
    1. Ferrari R., Panzali A. F., Poole-Wilson P. A., Anand S. (1991). Plasma CGRP-like immunoreactivity in treated and untreated congestive heart failure. Lancet 338:1084 10.1016/0140-6736(91)91944-P
    1. Franco-Cereceda A., Henke H., Lundberg J. M., Petermann J. B., Hökfelt T., Fischer J. A. (1987). Calcitonin gene-related peptide (CGRP) in capsaicin-sensitive substance P-immunoreactive sensory neurons in animals and man: distribution and release by capsaicin. Peptides 8 399–410. 10.1016/0196-9781(87)90117-3
    1. Fujioka S., Sasakawa O., Kishimoto H., Tsumura K., Morii H. (1991). The antihypertensive effect of calcitonin gene-related peptide in rats with norepinephrine- and angiotensin II-induced hypertension. J. Hypertens. 9 175–179. 10.1097/00004872-199102000-00013
    1. Gao Y., Song J., Chen H., Cao C., Lee C. (2015). TRPV1 activation is involved in the cardioprotection of remote limb ischemic postconditioning in ischemia-reperfusion injury rats. Biochem. Biophys. Res. Commun. 463 1034–1039. 10.1016/j.bbrc.2015.06.054
    1. Gennari C., Fischer J. A. (1985). Cardiovascular action of calcitonin gene-related peptide in humans. Calcif. Tissue Int. 37 581–584. 10.1007/BF02554909
    1. Gennari C., Nami R., Agnusdei D., Fischer J. A. (1990). Improved cardiac performance with human calcitonin gene related peptide in patients with congestive heart failure. Cardiovasc. Res. 24 239–241. 10.1093/cvr/24.3.239
    1. Gibbins I. L., Furness J. B., Costa M., MacIntyre I., Hillyard C. J., Girgis S. (1985). Co-localization of calcitonin gene-related peptide-like immunoreactivity with substance P in cutaneous, vascular and visceral sensory neurons of guinea pigs. Neurosci. Lett. 57 125–130. 10.1016/0304-3940(85)90050-3
    1. Goadsby P. J., Edvinsson L., Ekman R. (1990). Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28 183–187. 10.1002/ana.410280213
    1. Goadsby P. J., Reuter U., Hallström Y., Broessner G., Bonner J. H., Zhang F., et al. (2017). A controlled trial of erenumab for episodic migraine. N. Engl. J. Med. 377 2123–2132. 10.1056/NEJMoa1705848
    1. Gulbenkian S., Merighi A., Wharton J., Varndell I. M., Polak J. M. (1986). Ultrastructural evidence for the coexistence of calcitonin gene-related peptide and substance P in secretory vesicles of peripheral nerves in the guinea pig. J. Neurocytol. 15 535–542. 10.1007/BF01611735
    1. Hay D. L., Garelja M. L., Poyner D. R., Walker C. S. (2018). Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR review 25. Br. J. Pharmacol. 175 3–17. 10.1111/bph.14075
    1. Ho T. W., Connor K. M., Zhang Y., Pearlman E., Koppenhaver J., Fan X., et al. (2014). Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 83 958–966. 10.1212/WNL.0000000000000771
    1. Hsu J.-H., Yeh J.-L., Dai Z.-K., Chen I.-J., Wu J.-R. (2005). Increased circulating calcitonin gene-related peptide in congestive heart failure caused by congenital heart disease. Int. Heart J. 46 867–875. 10.1536/ihj.46.867
    1. Ishikawa T., Okamura N., Saito A., Masaki T., Goto K. (1988). Positive inotropic effect of calcitonin gene-related peptide mediated by cyclic AMP in guinea pig heart. Circ. Res. 63 726–734. 10.1161/01.RES.63.4.726
    1. Jäger K., Muench R., Seifert H., Beglinger C., Bollinger A., Fischer J. A. (1990). Calcitonin gene-related peptide (CGRP) causes redistribution of blood flow in humans. Eur. J. Clin. Pharmacol. 39 491–494. 10.1007/BF00280942
    1. Jancsó N., Jancsó-GáBor A., SzolcsáNyi J. (1967). Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br. J. Pharmacol. Chemother. 31 138–151. 10.1111/j.1476-5381.1967.tb01984.x
    1. Joyce C. D., Fiscus R. R., Wang X., Dries D. J., Morris R. C., Prinz R. A. (1990a). Calcitonin gene-related peptide levels are elevated in patients with sepsis. Surgery 108 1097–1101.
    1. Joyce C. D., Prinz R. A., Thomas J. X., Fiscus R. R., Wang X., Djuricin G., et al. (1990b). Calcitonin gene-related peptide increases coronary flow and decreases coronary resistance. J. Surg. Res. 49 435–440. 10.1016/0022-4804(90)90192-5
    1. Juhl L., Edvinsson L., Olesen J., Jansen-Olesen I. (2007). Effect of two novel CGRP-binding compounds in a closed cranial window rat model. Eur. J. Pharmacol. 567 117–124. 10.1016/j.ejphar.2007.04.004
    1. Katori T., Hoover D. B., Ardell J. L., Helm R. H., Belardi D. F., Tocchetti C. G., et al. (2005). Calcitonin gene-related peptide in vivo positive inotropy is attributable to regional sympatho-stimulation and is blunted in congestive heart failure. Circ. Res. 96 234–243. 10.1161/
    1. Kawasaki H., Nuki C., Saito A., Takasaki K. (1990). Role of calcitonin gene-related peptide-containing nerves in the vascular adrenergic neurotransmission. J. Pharmacol. Exp. Ther. 252 403–409.
    1. Kawasaki H., Okazaki M., Nakatsuma A., Mimaki Y., Araki H., Gomita Y. (1999). Long-term treatment with angiotensin converting enzyme inhibitor restores reduced calcitonin gene-related peptide-containing vasodilator nerve function in mesenteric artery of spontaneously hypertensive rats. Jpn. J. Pharmacol. 79 221–229. 10.1254/jjp.79.221
    1. Kawasaki H., Takenaga M., Araki H., Futagami K., Gomita Y. (1998). Angiotensin inhibits neurotransmission of calcitonin gene-related peptide-containing vasodilator nerves in mesenteric artery of spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 284 508–515.
    1. Kobayashi K., Fukuoka T., Obata K., Yamanaka H., Dai Y., Tokunaga A., et al. (2005). Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with adelta/c-fibers and colocalization with trk receptors. J. Comp. Neurol. 493 596–606. 10.1002/cne.20794
    1. Kraenzlin M. E., Ch’ng J. L., Mulderry P. K., Ghatei M. A., Bloom S. R. (1985). Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones. Regul. Pept. 10 189–197. 10.1016/0167-0115(85)90013-8
    1. Kurihara H., Shindo T., Oh-Hashi Y., Kurihar Y., Kuwaki T. (2003). Targeted disruption of adrenomedullin and alphaCGRP genes reveals their distinct biological roles. Hypertens. Res. 26(Suppl.), S105–S108. 10.1291/hypres.26.S105
    1. Kurtz A., Schurek H. J., Jelkmann W., Muff R., Lipp H. P., Heckmann U., et al. (1989). Renal mesangium is a target for calcitonin gene-related peptide. Kidney Int. 36 222–227. 10.1038/ki.1989.183
    1. Kuwasako K., Cao Y.-N., Chu C.-P., Iwatsubo S., Eto T., Kitamura K. (2006). Functions of the cytoplasmic tails of the human receptor activity-modifying protein components of calcitonin gene-related peptide and adrenomedullin receptors. J. Biol. Chem. 281 7205–7213. 10.1074/jbc.M511147200
    1. Li J., Levick S. P., DiPette D. J., Janicki J. S., Supowit S. C. (2013). Alpha-calcitonin gene-related peptide is protective against pressure overload-induced heart failure. Regul. Pept. 185 20–28. 10.1016/j.regpep.2013.06.008
    1. Li J., Wang D. H. (2005). Development of angiotensin II-induced hypertension: role of CGRP and its receptor. J. Hypertens. 23 113–118. 10.1097/00004872-200501000-00020
    1. Li J., Zhao H., Supowit S. C., Dipette D. J., Wang D. H. (2004). Activation of the renin-angiotensin system in alpha-calcitonin gene-related peptide/calcitonin gene knockout mice. J. Hypertens. 22 1345–1349. 10.1097/01.hjh.0000125409.50839.f1
    1. Li J.-Z., Peng J., Xiao L., Zhang Y.-S., Liao M.-C., Li X.-H., et al. (2010). Reversal of isoprenaline-induced cardiac remodeling by rutaecarpine via stimulation of calcitonin gene-related peptide production. Can. J. Physiol. Pharmacol. 88 949–959. 10.1139/y10-067
    1. Li Y. J., Xiao Z. S., Peng C. F., Deng H. W. (1996). Calcitonin gene-related peptide-induced preconditioning protects against ischemia-reperfusion injury in isolated rat hearts. Eur. J. Pharmacol. 311 163–167. 10.1016/0014-2999(96)00426-8
    1. Lind H., Brudin L., Lindholm L., Edvinsson L. (1996). Different levels of sensory neuropeptides (calcitonin gene-related peptide and substance P) during and after exercise in man. Clin. Physiol. 16 73–82. 10.1111/j.1475-097X.1996.tb00557.x
    1. Linscheid P., Seboek D., Schaer D. J., Zulewski H., Keller U., Müller B. (2004). Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit. Care Med. 32 1715–1721. 10.1097/01.CCM.0000134404.63292.71
    1. Liu Z., Liu Q., Cai H., Xu C., Liu G., Li Z. (2011). Calcitonin gene-related peptide prevents blood-brain barrier injury and brain edema induced by focal cerebral ischemia reperfusion. Regul. Pept. 171 19–25. 10.1016/j.regpep.2011.05.014
    1. Ludman P. F., Maseri A., Clark P., Davies G. J. (1991). Effects of calcitonin gene-related peptide on normal and atheromatous vessels and on resistance vessels in the coronary circulation in humans. Circulation 84 1993–2000. 10.1161/01.CIR.84.5.1993
    1. Lundberg J. M., Franco-Cereceda A., Hua X., Hökfelt T., Fischer J. A. (1985). Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. Eur. J. Pharmacol. 108 315–319. 10.1016/0014-2999(85)90456-X
    1. Lundberg J. M., Hua Y., Fredholm B. B. (1984). Capsaicin-induced stimulation of the guinea-pig atrium. Naunyn Schmiedebergs Arch. Pharmacol. 325 176–182. 10.1007/BF00506198
    1. MaassenVanDenBrink A., Meijer J., Villalón C. M., Ferrari M. D. (2016). Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol. Sci. 37 779–788. 10.1016/j.tips.2016.06.002
    1. Mai T., Wu J., Diedrich A., Garland E. M., Robertson D. (2014). Calcitonin gene related peptide (CGRP) in autonomic cardiovascular regulation and vascular structure. J. Am. Soc. Hypertens. 8 286–296. 10.1016/j.jash.2014.03.001
    1. Marshall I., Al-Kazwini S., Holman J., Craig R. (1988). Human alpha-calcitonin gene-related peptide (CGRP) is a potent vasodilator in human mesenteric vasculature. Br. J. Clin. Pharmacol. 26 691–695. 10.1111/j.1365-2125.1988.tb05306.x
    1. Marshall N. J., Liang L., Bodkin J., Dessapt-Baradez C., Nandi M., Collot-Teixeira S., et al. (2013). A role for TRPV1 in influencing the onset of cardiovascular disease in obesity. Hypertension 61 246–252. 10.1161/HYPERTENSIONAHA.112.201434
    1. Masuda A., Shimamoto K., Mori Y., Nakagawa M., Ura N., Iimura O. (1992). Plasma calcitonin gene-related peptide levels in patients with various hypertensive diseases. J. Hypertens. 10 1499–1504. 10.1097/00004872-199210120-00010
    1. Matteoli M., Haimann C., Torri-Tarelli F., Polak J. M., Ceccarelli B., De Camilli P. (1988). Differential effect of alpha-latrotoxin on exocytosis from small synaptic vesicles and from large dense-core vesicles containing calcitonin gene-related peptide at the frog neuromuscular junction. Proc. Natl. Acad. Sci. U.S.A. 85 7366–7370. 10.1073/pnas.85.19.7366
    1. McLatchie L. M., Fraser N. J., Main M. J., Wise A., Brown J., Thompson N., et al. (1998). RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393 333–339. 10.1038/30666
    1. Meens M. J., Mattheij N. J., van Loenen P. B., Spijkers L. J., Lemkens P., Nelissen J., et al. (2012). G-protein βγ subunits in vasorelaxing and anti-endothelinergic effects of calcitonin gene-related peptide. Br. J. Pharmacol. 166 297–308. 10.1111/j.1476-5381.2011.01774.x
    1. Messlinger K. (2018). The big CGRP flood - sources, sinks and signalling sites in the trigeminovascular system. J. Headache Pain 19:22 10.1186/s10194-018-0848-0
    1. Mishima T., Ito Y., Hosono K., Tamura Y., Uchida Y., Hirata M., et al. (2011). Calcitonin gene-related peptide facilitates revascularization during hindlimb ischemia in mice. Am. J. Physiol. Heart Circ. Physiol. 300 H431–H439. 10.1152/ajpheart.00466.2010
    1. Moreno M. J., Terrón J. A., Stanimirovic D. B., Doods H., Hamel E. (2002). Characterization of calcitonin gene-related peptide (CGRP) receptors and their receptor-activity-modifying proteins (RAMPs) in human brain microvascular and astroglial cells in culture. Neuropharmacology 42 270–280. 10.1016/S0028-3908(01)00176-9
    1. Mulderry P. K., Ghatei M. A., Bishop A. E., Allen Y. S., Polak J. M., Bloom S. R. (1985). Distribution and chromatographic characterisation of CGRP-like immunoreactivity in the brain and gut of the rat. Regul. Pept. 12 133–143. 10.1016/0167-0115(85)90194-6
    1. Nakajima T., Takikawa R., Sugimoto T., Kurachi Y. (1991). Effects of calcitonin gene-related peptide on membrane currents in mammalian cardiac myocytes. Pflugers Arch. 419 644–650. 10.1007/BF00370309
    1. Nilsson C., Hansen T. K., Rosenquist C., Hartmann B., Kodra J. T., Lau J. F., et al. (2016). Long acting analogue of the calcitonin gene-related peptide induces positive metabolic effects and secretion of the glucagon-like peptide-1. Eur. J. Pharmacol. 773 24–31. 10.1016/j.ejphar.2016.01.003
    1. O’Connor T. P., van der Kooy D. (1988). Enrichment of a vasoactive neuropeptide (calcitonin gene related peptide) in the trigeminal sensory projection to the intracranial arteries. J. Neurosci. 8 2468–2476. 10.1523/JNEUROSCI.08-07-02468.1988
    1. Olesen J., Diener H.-C., Husstedt I. W., Goadsby P. J., Hall D., Meier U., et al. (2004). Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350 1104–1110. 10.1056/NEJMoa030505
    1. Ozaka T., Doi Y., Kayashima K., Fujimoto S. (1997). Weibel-Palade bodies as a storage site of calcitonin gene-related peptide and endothelin-1 in blood vessels of the rat carotid body. Anat. Rec. 247 388–394. 10.1002/(SICI)1097-0185(199703)247:3<388::AID-AR10>;2-L
    1. Paemeleire K., MaassenVanDenBrink A. (2018). Calcitonin-gene-related peptide pathway mAbs and migraine prevention. Curr. Opin. Neurol. 31 274–280. 10.1097/WCO.0000000000000548
    1. Portaluppi F., Trasforini G., Margutti A., Vergnani L., Ambrosio M. R., Rossi R., et al. (1992). Circadian rhythm of calcitonin gene-related peptide in uncomplicated essential hypertension. J. Hypertens. 10 1227–1234. 10.1097/00004872-199210000-00017
    1. Pozsgai G., Hajna Z., Bagoly T., Boros M., Kemény Á, Materazzi S., et al. (2012). The role of transient receptor potential ankyrin 1 (TRPA1) receptor activation in hydrogen-sulphide-induced CGRP-release and vasodilation. Eur. J. Pharmacol. 689 56–64. 10.1016/j.ejphar.2012.05.053
    1. Preibisz J. J. (1993). Calcitonin gene-related peptide and regulation of human cardiovascular homeostasis. Am. J. Hypertens. 6 434–450. 10.1093/ajh/6.5.434
    1. Qi T., Ly K., Poyner D. R., Christopoulos G., Sexton P. M., Hay D. L. (2011). Structure–function analysis of amino acid 74 of human RAMP1 and RAMP3 and its role in peptide interactions with adrenomedullin and calcitonin gene-related peptide receptors. Peptides 32 1060–1067. 10.1016/j.peptides.2011.03.004
    1. Quallo T., Gentry C., Bevan S., Broad L. M., Mogg A. J. (2015). Activation of transient receptor potential ankyrin 1 induces CGRP release from spinal cord synaptosomes. Pharmacol. Res. Perspect. 3:e00191 10.1002/prp2.191
    1. Raffaelli B., Reuter U. (2018). The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy. Neurotherapeutics 15 324–335. 10.1007/s13311-018-0622-7
    1. Rosenfeld M. G., Mermod J.-J., Amara S. G., Swanson L. W., Sawchenko P. E., Rivier J., et al. (1983). Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304 129–135. 10.1038/304129a0
    1. Roudenok V., Gutjar L., Antipova V., Rogov Y. (2001). Expression of vasoactive intestinal polypeptide and calcitonin gene-related peptide in human stellate ganglia after acute myocardial infarction. Ann. Anat. 183 341–344. 10.1016/S0940-9602(01)80176-X
    1. Russell F. A., King R., Smillie S.-J., Kodji X., Brain S. D. (2014). Calcitonin gene-related peptide: physiology and pathophysiology. Physiol. Rev. 94 1099–1142. 10.1152/physrev.00034.2013
    1. Sacco S., Kurth T. (2014). Migraine and the risk for stroke and cardiovascular disease. Curr. Cardiol. Rep. 16:524 10.1007/s11886-014-0524-1
    1. Schifter S., Krusell L. R., Sehested J. (1991). Normal serum levels of calcitonin gene-related peptide (CGRP) in mild to moderate essential hypertension. Am. J. Hypertens. 4 565–569. 10.1093/ajh/4.7.565
    1. Schlereth T., Schukraft J., Krämer-Best H. H., Geber C., Ackermann T., Birklein F. (2016). Interaction of calcitonin gene related peptide (CGRP) and substance P (SP) in human skin. Neuropeptides 59 57–62. 10.1016/j.npep.2016.06.001
    1. Sekiguchi N., Kanatsuka H., Sato K., Wang Y., Akai K., Komaru T., et al. (1994). Effect of calcitonin gene-related peptide on coronary microvessels and its role in acute myocardial ischemia. Circulation 89 366–374. 10.1161/01.CIR.89.1.366
    1. Shang S., Zhu F., Liu B., Chai Z., Wu Q., Hu M., et al. (2016). Intracellular TRPA1 mediates Ca2+ release from lysosomes in dorsal root ganglion neurons. J. Cell Biol. 215 369–381. 10.1083/jcb.201603081
    1. Shekhar Y. C., Anand I. S., Sarma R., Ferrari R., Wahi P. L., Poole-Wilson P. A. (1991). Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure. Am. J. Cardiol. 67 732–736. 10.1016/0002-9149(91)90531-O
    1. Sheykhzade M., Abdolalizadeh B., Koole C., Pickering D. S., Dreisig K., Johansson S. E., et al. (2018). Vascular and molecular pharmacology of the metabolically stable CGRP analogue, SAX. Eur. J. Pharmacol. 829 85–92. 10.1016/j.ejphar.2018.04.007
    1. Sigrist S., Franco-Cereceda A., Muff R., Henke H., Lundberg J. M., Fischer J. A. (1986). Specific receptor and cardiovascular effects of calcitonin gene-related peptide. Endocrinology 119 381–389. 10.1210/endo-119-1-381
    1. Singh A., Randhawa P. K., Bali A., Singh N., Jaggi A. S. (2017). Exploring the role of TRPV and CGRP in adenosine preconditioning and remote hind limb preconditioning-induced cardioprotection in rats. Cardiovasc. Drugs Ther. 31 133–143. 10.1007/s10557-017-6716-3
    1. Smillie S.-J., Brain S. D. (2011). Calcitonin gene-related peptide (CGRP) and its role in hypertension. Neuropeptides 45 93–104. 10.1016/j.npep.2010.12.002
    1. Smillie S.-J., King R., Kodji X., Outzen E., Pozsgai G., Fernandes E., et al. (2014). An ongoing role of α-calcitonin gene–related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension 63 1056–1062. 10.1161/HYPERTENSIONAHA.113.02517
    1. Song S. W., Guo K. J., Shi R., Cheng Y., Liu Y. F. (2009). Pretreatment with calcitonin gene-related peptide attenuates hepatic ischemia/reperfusion injury in rats. Transplant. Proc. 41 1493–1498. 10.1016/j.transproceed.2009.03.056
    1. Stauffer V. L., Dodick D. W., Zhang Q., Carter J. N., Ailani J., Conley R. R. (2018). Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 10.1001/jamaneurol.2018.1212 [Epub ahead of print].
    1. Struthers A. D., Brown M. J., Macdonald D. W. R., Beacham J. L., Stevenson J. C., Morris H. R., et al. (1986). Human calcitonin gene related peptide: a potent endogenous vasodilator in man. Clin. Sci. 70 389–393. 10.1042/cs0700389
    1. Supowit S. C., Ramana C. V., Westlund K. N., Di Pette D. J. (1993). Calcitonin gene-related peptide gene expression in the spontaneously hypertensive rat. Hypertension 21 1010–1014. 10.1161/01.HYP.21.6.1010
    1. Supowit S. C., Zhao H., Hallman D. M., DiPette D. J. (1997). Calcitonin gene-related peptide is a depressor of deoxycorticosterone-salt hypertension in the rat. Hypertension 29 945–950. 10.1161/01.HYP.29.4.945
    1. Takenaga M., Kawasaki H. (1999). Endogenous calcitonin gene-related peptide suppresses vasoconstriction mediated by adrenergic nerves in rat mesenteric resistance blood vessels. Eur. J. Pharmacol. 367 239–245. 10.1016/S0014-2999(98)00949-2
    1. Taquet H., Komajda M., Grenier O., Belas F., Landault C., Carayon A., et al. (1992). Plasma calcitonin gene-related peptide decreases in chronic congestive heart failure. Eur. Heart J. 13 1473–1476. 10.1093/oxfordjournals.eurheartj.a060088
    1. Terenghi G., Polak J. M., Ghatei M. A., Mulderry P. K., Butler J. M., Unger W. G., et al. (1985). Distribution and origin of calcitonin gene-related peptide (CGRP) immunoreactivity in the sensory innervation of the mammalian eye. J. Comp. Neurol. 233 506–516. 10.1002/cne.902330410
    1. Tortorella C., Macchi C., Forneris M., Nussdorfer G. G. (2001). Calcitonin gene-related peptide (CGRP), acting via CGRP type 1 receptors, inhibits potassium-stimulated aldosterone secretion and enhances basal catecholamine secretion from rat adrenal gland. Int. J. Mol. Med. 8 261–264. 10.3892/ijmm.8.3.261
    1. Van der Schueren B. J., Rogiers A., Vanmolkot F. H., Van Hecken A., Depré M., Kane S. A., et al. (2008). Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic model. J. Pharmacol. Exp. Ther. 325 248–255. 10.1124/jpet.107.133868
    1. Vatner D. E., Sato N., Ishikawa Y., Kiuchi K., Shannon R. P., Vatner S. F. (1996). Beta-adrenoceptor desensitization during the development of canine pacing-induced heart failure. Clin. Exp. Pharmacol. Physiol. 23 688–692. 10.1111/j.1440-1681.1996.tb01760.x
    1. Venkatachalam K., Montell C. (2007). TRP Channels. Annu. Rev. Biochem. 76 387–417. 10.1146/annurev.biochem.75.103004.142819
    1. Viana F. (2016). TRPA1 channels: molecular sentinels of cellular stress and tissue damage. J. Physiol. 594 4151–4169. 10.1113/JP270935
    1. Wang H., Xing L., Li W., Hou L., Guo J., Wang X. (2002). Production and secretion of calcitonin gene-related peptide from human lymphocytes. J. Neuroimmunol. 130 155–162. 10.1016/S0165-5728(02)00221-7
    1. Wang W., Zhu G.-Q., Gao L., Tan W., Qian Z.-M. (2004). Baroreceptor reflex in heart failure. Sheng Li Xue Bao 56 269–281.
    1. Weston C., Winfield I., Harris M., Hodgson R., Shah A., Dowell S. J., et al. (2016). Receptor activity-modifying protein-directed g protein signaling specificity for the calcitonin gene-related peptide family of receptors. J. Biol. Chem. 291 21925–21944. 10.1074/jbc.M116.751362
    1. Wolfrum S., Nienstedt J., Heidbreder M., Schneider K., Dominiak P., Dendorfer A. (2005). Calcitonin gene related peptide mediates cardioprotection by remote preconditioning. Regul. Pept. 127 217–224. 10.1016/j.regpep.2004.12.008
    1. Yao G., Yu T., Han X., Mao X., Li B. (2013). Therapeutic effects and safety of olcegepant and telcagepant for migraine: a meta-analysis. Neural Regen. Res. 8 938–947. 10.3969/j.issn.1673-5374.2013.10.009
    1. Zaidi M., Brain S. D., Tippins J. R., Di Marzo V., Moonga B. S., Chambers T. J., et al. (1990). Structure-activity relationship of human calcitonin-gene-related peptide. Biochem. J. 269 775–780. 10.1042/bj2690775
    1. Zeller J., Poulsen K. T., Sutton J. E., Abdiche Y. N., Collier S., Chopra R., et al. (2008). CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br. J. Pharmacol. 155 1093–1103. 10.1038/bjp.2008.334
    1. Zheng J. (2013). Molecular mechanism of TRP channels. Compr. Physiol. 3 221–242. 10.1002/cphy.c120001

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel